Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.